Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Thursday. They currently have a $14.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 38.75% from the stock’s current price.

A number of other equities analysts have also recently commented on SPPI. Jefferies Group LLC set a $9.00 target price on Spectrum Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, June 8th. Zacks Investment Research upgraded Spectrum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 target price for the company in a report on Wednesday, August 9th. BidaskClub cut Spectrum Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Finally, ValuEngine upgraded Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 17th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $10.80.

Shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) remained flat at $10.09 during mid-day trading on Thursday. 507,864 shares of the company were exchanged. Spectrum Pharmaceuticals has a 1-year low of $3.21 and a 1-year high of $10.77. The company has a 50-day moving average of $9.08 and a 200-day moving average of $7.28. The stock’s market cap is $792.83 million.

Spectrum Pharmaceuticals (NASDAQ:SPPI) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.01. The business had revenue of $34.30 million during the quarter, compared to analysts’ expectations of $30.50 million. Spectrum Pharmaceuticals had a negative return on equity of 30.95% and a negative net margin of 59.33%. The firm’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.35) EPS. Equities research analysts predict that Spectrum Pharmaceuticals will post ($1.03) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “HC Wainwright Reiterates “Buy” Rating for Spectrum Pharmaceuticals, Inc. (SPPI)” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/14/hc-wainwright-reiterates-buy-rating-for-spectrum-pharmaceuticals-inc-sppi-2.html.

Institutional investors have recently made changes to their positions in the company. State of Alaska Department of Revenue boosted its holdings in shares of Spectrum Pharmaceuticals by 77.1% in the 2nd quarter. State of Alaska Department of Revenue now owns 13,918 shares of the biotechnology company’s stock worth $103,000 after purchasing an additional 6,058 shares during the period. Piedmont Investment Advisors LLC purchased a new position in shares of Spectrum Pharmaceuticals in the 2nd quarter worth approximately $114,000. Denver Investment Advisors LLC purchased a new position in shares of Spectrum Pharmaceuticals in the 1st quarter worth approximately $106,000. Mason Street Advisors LLC boosted its holdings in shares of Spectrum Pharmaceuticals by 8.4% in the 1st quarter. Mason Street Advisors LLC now owns 16,577 shares of the biotechnology company’s stock worth $108,000 after purchasing an additional 1,279 shares during the period. Finally, Municipal Employees Retirement System of Michigan boosted its holdings in shares of Spectrum Pharmaceuticals by 5.6% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 16,720 shares of the biotechnology company’s stock worth $125,000 after purchasing an additional 880 shares during the period. Hedge funds and other institutional investors own 66.09% of the company’s stock.

Spectrum Pharmaceuticals Company Profile

Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).

Receive News & Ratings for Spectrum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.